一种安宫牛黄丸及制备方法
By preparing lyophilized microspheres of biomimetic rhinoceros horn biological agents, the problem of insufficient dosage form optimization of rhinoceros horn substitutes has been solved, achieving sustained efficacy and highly effective antipyretic and anti-inflammatory effects, which are suitable for acute treatment.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- SHANXI YUANHUA TECHNOLOGY CO LTD
- Filing Date
- 2025-11-27
- Publication Date
- 2026-07-17
AI Technical Summary
Existing rhinoceros horn alternatives lack dosage form optimization and cannot meet the sustained efficacy requirements of acute treatment. Chemically synthesized keratin cannot form intermolecular interactions with traditional Chinese medicine ingredients, resulting in reduced bioavailability.
Using biomimetic rhinoceros horn biological agents, freeze-dried microspheres with a diameter of 50μm-100μm are prepared through gene engineering expression, compound enzymatic hydrolysis and high pressure homogenization technology. These microspheres contain recombinant keratin, buffalo horn enzymatic hydrolysis active peptides and silk fibroin, and are combined with medicinal materials such as Scutellaria baicalensis to form Angong Niuhuang Wan with specific release characteristics.
It achieves antipyretic and anti-inflammatory effects equivalent to natural rhinoceros horn, significantly superior to traditional buffalo horn substitutes, improves the bioavailability of baicalin and prolongs its efficacy, and is suitable for the treatment of acute conditions such as febrile seizures and coma due to cerebral hemorrhage.
Smart Images
Figure CN121371124B_ABST